A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors

The objective of this study was to investigate the safety and the tolerability of combined cellular immunotherapy with low-dose cyclophosphamide (CPA) in patients with advanced solid tumors. This study targeted a novel tumor-associated antigen, ring finger protein 43 (RNF43). Eligible patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijikata, Yasuki, Okazaki, Toshihiko, Tanaka, Yoshihiro, Murahashi, Mutsunori, Yamada, Yuichi, Yamada, Kazunari, Takahashi, Atsushi, Inoue, Hiroyuki, Kishimoto, Junji, Nakanishi, Yoichi, Oda, Yoshinao, Nakamura, Yusuke, Tani, Kenzaburo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749706/
https://www.ncbi.nlm.nih.gov/pubmed/29293510
http://dx.doi.org/10.1371/journal.pone.0187878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749706/
https://www.ncbi.nlm.nih.gov/pubmed/29293510
http://dx.doi.org/10.1371/journal.pone.0187878

Ejemplares similares